Work

P-109 Broaden the therapeutic opportunities for colorectal cancer: ALK inhibition benefits consensus molecular subtype 1 patients

Year: 2023

Type: conference-abstract

Source: Annals of Oncology

DOI: 10.1016/j.annonc.2023.04.165

Authors: M. Mazzeschi, M. Sgarzi, D. Romaniello, F. Ambrosi, A. Morselli, C. Girone, F. Pagano, K. Rihawi, G. D'Uva, M. Ferracin, M. Fiorentino, A. Ardizzoni, B. Győrffy, R. Palmer, N. Li, C. Lengner, Y. Mossé, M. Lauriola

Institutions: IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola, University of Bologna, Ospedale Maggiore Carlo Alberto Pizzardi, Semmelweis University, University of Gothenburg, University of Pennsylvania, Children's Hospital of Philadelphia

Language: English

Topic: Colorectal Cancer Treatments and Studies

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W4382806773

Cites:

Cited by:

Related to: 10